ConductScience.org, home

Paper41275111

Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial.

Takeshima T and 8 others. J Headache Pain, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial. Papers, record 41275111. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41275111

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial.
PubMed
Journal
J Headache Pain
PubMed
Year
2025
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-06-30
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Takeshima TTakao
2Danno DDaisukehttps://orcid.org/0000-0003-3737-4754
3Imai NNoboru
4Suzuki KKeisuke
5Ettrup AAndershttps://orcid.org/0000-0002-8926-3012
6Jensen SSidsel
7Josiassen MKMette Krog
8Mittoux AAuréliahttps://orcid.org/0000-0003-2449-807X
9Matsumori YYasuhiko

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnalgesicsMajor topic
Migraine DisordersMajor topic
Adult
Female
Humans
Male
Middle Aged
Chronic Disease
Double-Blind Method
Japan
Treatment Outcome
East Asian People
Antibodies, Monoclonal, Humanized

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05064371Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in JapanDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135690723European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.J Headache Pain2022https://conductscience.org/library/papers/35690723PubMed
239708221The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study.Neurol Ther2025https://conductscience.org/library/papers/39708221PubMed
322193671The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.Am J Psychiatry2011https://conductscience.org/library/papers/22193671PubMed
439700106Clinical practice for migraine treatment and characteristics of medical facilities and physicians treating migraine: Insights from a retrospective cohort study using a Japanese claims database.PLoS One2024https://conductscience.org/library/papers/39700106PubMed
539661241The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Region.Pain Ther2025https://conductscience.org/library/papers/39661241PubMed
634862581Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study.Neurol Ther2022https://conductscience.org/library/papers/34862581PubMed
735716692
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Lancet Neurol2022https://conductscience.org/library/papers/35716692PubMed
821479777Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).Qual Life Res2011https://conductscience.org/library/papers/21479777PubMed
931174464Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme.J Headache Pain2019https://conductscience.org/library/papers/31174464PubMed
1035466430Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.Headache2022https://conductscience.org/library/papers/35466430PubMed
1133023473
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
J Headache Pain2020https://conductscience.org/library/papers/33023473PubMed
1232209650Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.Neurology2020https://conductscience.org/library/papers/32209650PubMed
1310146874The validity and reproducibility of a work productivity and activity impairment instrument.Pharmacoeconomics1993https://conductscience.org/library/papers/10146874PubMed
1434013992Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.Headache2021https://conductscience.org/library/papers/34013992PubMed
1529368949Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.Cephalalgia2018https://conductscience.org/library/papers/29368949PubMed
1638523607Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review.Front Neurol2024https://conductscience.org/library/papers/38523607PubMed
1739692817Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial.J Patient Rep Outcomes2024https://conductscience.org/library/papers/39692817PubMed
189595870Development and validation of the Migraine-Specific Quality of Life Questionnaire.Headache1998https://conductscience.org/library/papers/9595870PubMed
1938664605Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study.J Headache Pain2024https://conductscience.org/library/papers/38664605PubMed
2028919117
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
Lancet2017https://conductscience.org/library/papers/28919117PubMed

See all 43 referencesDownload CSV of references

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
EPTINEZUMABCHEMBL3833320Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3833320

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Cited by
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41275111

GET https://conductscience.org/api/papers/v1/41275111/references?page=2